Withdrawals from the drug benefits - August 2019

8 July 2019 - Etalpha 80 mg & 100 capsules, Leflunomide medac 15 mg & 30 tablets and Maviret 100 mg ...

Read more →

Gefitinib in new exchange group

28 June 2019 - As of June, gefitinib is included as an exchange group on the list of period goods. ...

Read more →

Joint evaluation report of sotagliflozin (Zynquista)

28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...

Read more →

Health economic assessment of Kymriah in diffuse large B-cell lymphoma

20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...

Read more →

TLV does not extend Hemlibra's current subsidy

18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients ...

Read more →

Review of Rotarix

12 June 2019 - TLV has decided to initiate a review of the drug Rotarix due to the Government's decision ...

Read more →

TLV publishes first joint report within the FINOSE co-operation

11 June 2019 - FINOSE is a collaboration between the HTA authorities, the pharmaceutical company Fimea (Finland), the Norwegian Medicines Agency, ...

Read more →

Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease

29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene ...

Read more →

More patients get access to medicines within the high-cost protection

29 May 2019 - From June 2 next year, patients who obtain prescription drugs at pharmacies will be able to ...

Read more →

Health economic assessment of Opdivo in combination with Yervoy for the first-line treatment of patients with renal cell carcinoma

27 May 2019 - TLV has produced a health economic knowledge base for the regions of the drug Opdivo (nivolumab) in ...

Read more →

Health economic assessment of Tegsedi in hereditary transthyretin amyloidosis

17 May 2019 - TLV has produced a health economic knowledge base for the regions for Tegsedi (inotersen) that treat hereditary ...

Read more →

Time to entry for new cancer medicines: from European Union wide marketing authorisation to patient access in Belgium, Estonia, Scotland, and Sweden

10 July 2018 - This study quantified the median time from European Union wide approval to first use for a ...

Read more →

Vertex reaches agreement in Sweden for reimbursement of Orkambi

18 June 2018 - Vertex Pharmaceuticals announced that Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic ...

Read more →

Patients call for end to two-year row over cystic fibrosis drug funding

19 June 2018 - UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families ...

Read more →

Sweden launches campaign to host EU drugs agency instead of UK after Brexit

8 December 2016 - Britain's negotiations over leaving the EU have not even begun and already European countries are vying ...

Read more →